16:38 , Jul 18, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibition of BACH1 or the genes it controls for metastatic lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting the pro-metastatic transcription factor BACH1 or its gene targets MCT1, HMOX1, HK2 and GADPH could treat metastatic lung cancer. In patients with metastasized lung cancer, levels of BACH1...
21:58 , Dec 15, 2017 |  BioCentury  |  Emerging Company Profile

CD38 hat trick

Tusk Therapeutics Ltd. thinks its anti-CD38 mAb could be best in class for solid tumors because it not only kills cancer cells and inhibits immunosuppressive cells, as its competitors do, but it also directly activates...
19:20 , Nov 17, 2017 |  BC Week In Review  |  Company News

Sixth Element, PhoreMost spin out immuno-oncology newco

Sixth Element Capital LLC invested £3 million ($4 million) in newly created NeoPhore Ltd. (Cambridge, U.K.), a spinout from cancer company PhoreMost Ltd. (Cambridge, U.K.). The newco will seek to discover and develop small molecule...
23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
23:39 , Aug 29, 2017 |  BC Extra  |  Company News

Forma adds $195M cash after Celgene extends collaboration

Forma Therapeutics Inc. (Watertown, Mass.) pocketed $195 million in cash up front after Celgene Corp. (NASDAQ:CELG) exercised a 2014 option to enter a second deal to discover and develop additional compounds targeting undisclosed protein families...
22:38 , Jul 20, 2017 |  BC Innovations  |  Finance

Sharpless edge for NCI

The National Cancer Institute is poised to enter a new phase, under the leadership of Norman (Ned) Sharpless, following the June 9 announcement by the White House of the president’s choice to fill the large...
19:09 , Jul 14, 2017 |  BC Week In Review  |  Company News

Cancer Research UK and Merck KGaA extend 2015 deal to discover Hippo-YAP pathway therapies

The Cancer Research Technology (CRT) commercial arm of Cancer Research UK (London, U.K.) said it extended a 2015 deal with Merck KGaA (Xetra:MRK) to discover cancer treatments targeting the Hippo- yes-associated protein 1 ( YAP1...
20:45 , Jul 7, 2017 |  BC Week In Review  |  Company News

Merck KGaA spins out cancer newco iOnctura with partner Cancer Research UK

Merck KGaA (Xetra:MRK) said that its Merck Ventures arm created immuno-oncology newco iOnctura S.A. (Geneva, Switzerland) with an undisclosed seed investment. The newco launched with two unnamed assets spun out of Merck’s Healthcare R&D portfolio,...
16:55 , Jun 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse studies suggest inhibiting HspA5 could help treat pancreatic ductal adenocarcinoma (PDAC). In male and female mouse models of PDAC, HspA5 knockdown decreased number of ducts with acinar-to-ductal metaplasia, Pancreatic Intraepithelial Neoplasias...
01:01 , Apr 28, 2017 |  BC Innovations  |  Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...